AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio is viewed favorably because its core value is increasingly tied to Jemperli, whose global net sales reached $331M in 2Q26, $644M in 1H26, and an annualized $1.4B in 4Q25, reflecting strong 26% YoY and 34% YoY growth that supports a durable and expanding royalty stream. The company also has meaningful upside optionality from multiple near-term catalysts, including the October 25 AZUR-1 readout, the October 20 post-trial argument in the GSK royalty dispute with judgment expected in 4Q26/1Q27, the February 2027 PDUFA for rectal cancer, and the December 12, 2026 PDUFA for Quimilza, each of which could enhance visibility and increase future royalty revenue. Fundamentally, the long-duration nature of Jemperli’s patent life through 2035 in the U.S., 2036 in Europe, and 2037 in Japan, combined with management’s expectation of more than $390M in annualized Jemperli royalties as early as 2029 and potential expansion into colorectal cancer and other tumor types, underpins a constructive long-term outlook despite litigation and clinical development risk.

AnaptysBio is fundamentally challenged by the fact that its valuation and operational progress remain heavily dependent on clinical and regulatory outcomes rather than recurring product revenue, while its wholly owned pipeline is still concentrated in development-stage assets such as rosnilimab and ANB032 across Phase 2b and Phase 2 trials in RA, UC, and AD. The share count is also meaningfully dilutive, with 29.7M primary shares outstanding as of 6/30/26 and 37.3M fully diluted shares including 1.5M RSUs and 6.1M options, of which 3.6M are currently exercisable, which increases the burden on future per-share value creation. Although GSK’s Jemperli sBLA has been accepted for priority review with a February 2027 PDUFA date and potential earlier decision through Project Orbis or the CNPV program, that external catalyst does not materially de-risk AnaptysBio’s core investment case because the company’s own pipeline still faces substantial binary clinical and regulatory uncertainty.